Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31205892 | 0.81 | KDR (0.39) | KDROGA | |
| SCHEMBL8500994 | 0.73 | KDR (0.46) | KDR | |
| SCHEMBL3240449 | 0.73 | MEN1 (0.47) | KDR | |
| SCHEMBL19130973 | 0.70 | CSF1R (0.39) | KDR | |
| SCHEMBL17459121 | 0.69 | HCK (0.58) | KDR | |
| SCHEMBL559293 | 0.68 | CYP1A2 (0.51) | — | |
| SCHEMBL558521 | 0.68 | SMN1; SMN2 (0.54) | — | |
| SCHEMBL8499369 | 0.67 | CCR1 (0.46) | KDR | |
| SCHEMBL8499717 | 0.67 | KDM4E (0.47) | KDR | |
| SCHEMBL31051471 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | disclosed |
| EP-1758892-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-10-17 | — | — | EP | disclosed |
| CN-1960988-B | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2012-01-25 | — | — | CN | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | disclosed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | disclosed |
| CN-1960988-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-05-09 | — | — | CN | disclosed |
| EP-1758892-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123719-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, PTK2B, SRC | KDR 311/4885OGA 3981/4885CYP17A1 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.